Zosano Pharma Corp (ZSAN) [Rocket]

In millions, except per share items	Mar-31-22	Dec-31-21	Sep-30-21	Mar-31-21	Dec-31-20	Sep-30-20	Jun-30-20	Mar-31-20
	10-Q	10-K	10-Q	10-Q	10-K	10-Q	10-Q	10-Q
ASSETS
Current assets:
Cash and cash equivalents	13.5	11.0	17.1	26.9	35.3	43.6	10.5	18.6
Accounts receivable	0.1	0.1
Prepaid expenses and other current assets	2.1	0.4	1.1	1.9	0.5	0.6	0.7	0.6
Total current assets	15.6	11.6	18.1	28.5	35.7	44.2	11.2	19.2
Restricted cash	0.5
Property and equipment, net	7.9	32.6	32.3	32.1	30.9	30.6	30.7	30.2
Operating lease right-of-use assets	2.4	3.8	4.1	4.7	4.9	5.2	5.3	5.5
Total assets	26.4	48.4	55.0	65.7	72.0	80.5	47.7	55.3

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	3.7	2.1	1.6	2.7	1.9	2.0	4.8	3.3
Accrued compensation	0.5	1.8	1.9	2.7	2.3	2.0	2.8	2.6
Build-to-suit obligation, current portion, net of debt issuance costs and discount	1.7	3.8	4.5	4.7	4.8
Operating lease liabilities, current portion	1.6	1.6	1.6	1.4	1.4	1.3	1.2	1.2
Other accrued liabilities	2.2	1.8	2.1	1.5	3.4	3.4	3.9	8.9
Total current liabilities	9.7	11.1	11.6	14.4	14.5	13.2	16.5	20.6
Build-to-suit obligation, long-term portion, net of debt issuance costs and discount		1.0	1.4	3.4	4.4	5.4	6.5	5.1
Operating lease liabilities, long-term portion	2.7	3.1	3.5	4.3	4.7	5.1	5.3	5.6
Other long-term liabilities		0.2	0.2	0.2	0.1	0.1	0.0	0.0
Total liabilities	12.4	15.4	16.8	22.6	24.5	25.2	29.2	31.4

Commitments and contingencies (see note 11)
Stockholders’ equity:
Common stock		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional paid-in capital	409.6	395.1	393.3	383.5	379.7	379.3	333.9	331.5
Accumulated deficit	-395.5	-362.1	-355.1	-340.3	-332.2	-324.1	-315.4	-307.5
Total stockholders’ equity	14.1	33.0	38.2	43.2	47.5	55.2	18.5	24.0
Total liabilities and stockholders’ equity	26.4	48.4	55.0	65.7	72.0	80.5	47.7	55.3